StockData
AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31

ArriVent BioPharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$17.94+1.28 (+7.68%)

Close on Oct 19, 2026

Market cap
$854.07M
P/E (TTM)
–
Dividend yield
–

ArriVent BioPharma, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

ArriVent BioPharma does not break out revenue by segment, region or product in the tagged data of its filings for this period type.